References
- von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., Talbot D., Rey A., Butler T.W., Hirsh V., Olver I., Bergman B., Ayoub J., Richardson G., Dunlop D., Arcenas A., Vesico R., Viallet J., Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. Journal of Clinical Oncology 2000; 18: 1351–1359
- Wouters B.G., Lang L.H., Brown J.M. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Annals of Oncology 1999; 10(Supplement 5)S29–S33
- Brown J.M. SR4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. British Journal of Cancer 1993; 67: 1163–1170
- Baker M.A., Zeman E.M., Hirst V.K., Brown J.M. Metabolism of SR4233 by Chinese hamster ovary cells: basis of selective toxicity. Cancer Research 1988; 48: 5947–5952
- Tocher J.H., Virk N.S., Edwards D.I. Electrochemical studies and DNA damaging effects of the benzotriazine-N-oxides. Biochemical Pharmacology 1990; 39: 781–786
- Evans J.W., Yudoh K., Dalahoussaye Y.M., Brown J.M. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Research 1998; 58: 2098–2101
- Hwang J.T., Greenberg M.M., Gates K.S. Reaction of the hypoxia-selective antitumour agent tirapazamine with the C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 1999; 38: 14248–14255
- Tocher J.H., Virk N.S., Edwards D.I. DNA damaging effects and voltammetric studies of the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH. Biochemical Pharmacology 1990; 40: 1405–1410
- Tocher J.H., Edwards D.I. Electrochemical studies of tirapazamine: generation of the one-electron reduction product. Free Radical Research 1994; 21: 277–283
- Tocher J.H., Edwards D.I. Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochemical Pharmacology 1994; 48: 1089–1094
- Tocher J.H., Edwards D.I., Thomas A. The reactivity of chloramphenicol reduction products with DNA bases. International Journal of Radiation Oncology, Biology and Physics 1994; 29: 307–310
- Rowley D.A., Knight R.C., Skolimowski I.M., Edwards D.I. The effect of nitroheterocyclic drugs on DNA: an in vitro model of cytotoxicity. Biochemical Pharmacology 1979; 28: 3009–3013
- Laderoute K., Wardman P., Rauth A.M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR4233). Biochemical Pharmacology 1988; 37: 1487–1495
- Walmsley R. Effects of the benzotriazine-di-N-oxide tirapazamine upon DNA. PhD Thesis. University of East London. 1995
- Virk N.S. DNA damaging effects of benzotriazine-N-oxides. PhD Thesis. University of East London. 1993
- Elwell J.H., Siim B.G., Evans J.W., Brown J.M. Adaptation of human tumor cell lines to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochemical Pharmacology 1997; 54: 249–257
- Rauth A.M., Melo T., Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. International Journal of Radiation Oncology, Biology and Physics 1998; 42: 755–762